Hims & Hers Health, Inc.

Hims & Hers Health, Inc. announced the completion of its acquisition of Eucalyptus, a move expected to solidify its position as the world's largest consumer health platform. This strategic acquisition expands Hims & Hers' global reach across key markets including the US, UK, Australia, and Canada, with further expansion into Europe and Japan. The company reiterated its long-term financial targets of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030. Concurrently, Hims & Hers amended its revolving credit agreement to facilitate the acquisition, which involved changes to covenants and investment capacity.

Hims & Hers Health, Inc. announced the issuance of $402.5 million in aggregate principal amount of 0.00% Convertible Senior Notes due June 1, 2032. These notes are senior, unsecured obligations and do not bear regular interest. Noteholders have the right to convert their notes into cash, Class A common stock, or a combination, at the company's election, with an initial conversion price of approximately $29.53 per share. The company also entered into base and additional call option transactions to hedge potential dilution from the convertible notes.

Hims & Hers Health, Inc. announced the pricing of an upsized $350 million aggregate principal amount of 0.00% convertible senior notes due 2032 in a private offering. The offering size was increased from the previously announced $300 million. The estimated net proceeds of approximately $338.5 million will be used to preserve financial flexibility for international expansion, including the proposed acquisition of Eucalyptus, and to invest in technology, fulfillment infrastructure, and AI capabilities. The initial conversion price is $29.53 per share, representing a 32.5% premium over the company's Class A common stock closing price on May 18, 2026.

Hims & Hers Health, Inc. announced its Q1 2026 financial results, reporting a net loss of $92.1 million, a significant shift from a net income of $49.5 million in Q1 2025. This quarter included a major strategic move to acquire Eucalyptus, an Australia-based digital health company, for up to $1.15 billion, aiming to expand its international presence. The company also incurred $33.5 million in restructuring charges related to a strategic shift in its US weight loss offering. Revenue increased to $608.1 million, up from $586.0 million year-over-year.

Hims & Hers Health, Inc. announced first-quarter 2026 financial results, with revenue increasing 4% year-over-year to $608.1 million and subscribers growing 9% to nearly 2.6 million. Despite reporting a net loss of $92.1 million and a decrease in Adjusted EBITDA, the company raised its full-year 2026 revenue guidance to $2.8 billion to $3.0 billion and updated its Adjusted EBITDA guidance. The company highlighted a strategic pivot to branded GLP-1 products and expansion into new categories and countries.

Hims & Hers Health, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on Thursday, June 11, 2026. Stockholders will vote on the election of nine director nominees, including new nominee Kofi Amoo-Gottfried, and the ratification of KPMG LLP as the independent auditor for fiscal year 2026. The board size is set to decrease from ten to nine directors with two current directors not being renominated. The filing also highlighted strong FY 2025 financial performance, including $2.35B in revenue and $128.4M in net income.